Ibio (IBIO) AI Stock Analysis

• Market Cap: $47.22M
• Dividend Yield: N/A
• Average Volume (3M): 2.30M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.41
• Revenue Growth: 185.71%
• EPS Growth: 79.03%
• Country: US
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 22,487,309
• 10 Day Avg. Volume: 956,574
• 30 Day Avg. Volume: 2,295,568
• PEG Ratio: <0.01
• Price to Book (P/B): 0.54
• Price to Sales (P/S): 20.03
• P/FCF Ratio: -0.52
• Enterprise Value/Market Cap: 0.21
• Enterprise Value/Revenue: 19.79
• Enterprise Value/Gross Profit: 46.90
• Enterprise Value/Ebitda: -0.53
• 1Y Price Target: $5.50
• Price Target Upside: 139.13% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $2.00 ▼(-13.04% Downside)

The score is held back primarily by weak financial performance (minimal revenue, large losses, and sustained cash burn). Offsetting this are improving/low leverage and supportive corporate developments (financing extending runway), alongside strong technical momentum with the stock trading above major moving averages.

Positive Factors

Proprietary production platform

Ibio’s FastPharming plant-based protein platform is a durable competitive asset: it enables potentially lower-cost, scalable biologic production versus traditional cell culture, supports faster iteration for vaccine/therapeutic candidates, and enhances licensing and partnership appeal over the medium term.

Low leverage and improved balance sheet

Very low reported leverage provides financial flexibility for a development-stage biotech. Reduced debt burdens lower solvency risk, preserve optionality for multi-year R&D programs, and improve the company’s ability to pursue partnerships or staged financings without immediate balance-sheet distress.

Committed funding extends runway

The ~$26M private placement earmarked for preclinical pipeline work materially extends cash runway into 2028. This funding reduces near-term financing pressure, allowing completion of key preclinical studies and milestone generation that can de-risk assets and enable partnering or licensing discussions.

Negative Factors

Minimal revenue with large operating losses

TTM revenue near $0.5M while incurring ~-$20M EBIT and net losses shows the company remains pre-commercial. Persistent large operating losses mean long reliance on external capital and a lengthy path before sustainable commercial revenues can cover fixed costs and fund growth internally.

Sustained negative cash flow

Operating and free cash flow around -$17.3M TTM indicate ongoing cash burn. Continued negative cash generation increases the risk of repeated financings, potential dilution, and management distraction from execution to capital raises unless revenue scales or costs are materially reduced.

Negative margins and weak returns

Although gross margin appears healthy, operating and net margins are deeply negative and ROE is sharply negative. This structural mismatch shows the cost base is far ahead of current revenue, requiring substantial scale or cost restructuring to produce sustainable returns for shareholders.

Ibio Business Overview & Revenue Model

Company Description

iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.

How the Company Makes Money

Ibio generates revenue through a combination of product sales, research and development collaborations, and licensing agreements. The company partners with other biotech firms and academic institutions to co-develop its products, sharing in the financial benefits of successful outcomes. Additionally, Ibio may receive upfront payments, milestone payments, and royalties from its partners based on the sales of products developed using its technology. The revenue model is further supported by grants and contracts, particularly for vaccine development and other projects that align with public health initiatives.

Ibio Financial Statement Overview

Summary

Financial profile is weak overall: very small TTM revenue (~$0.5M) with deeply negative profitability (EBIT ~-$20.4M; net income ~-$20.1M) and significant ongoing cash burn (TTM operating and free cash flow ~-$17.3M). The main support is a healthier balance sheet with low leverage in TTM (debt-to-equity ~0.06), though returns remain sharply negative (ROE ~-0.84).

Income Statement

TTM (Trailing-Twelve-Months) revenue is very small ($0.5M) despite a strong percentage increase (+25%), and profitability remains deeply negative with large operating and net losses (EBIT about -$20.4M; net income about -$20.1M). Gross margin is positive (~42%), but operating and net margins are materially negative, indicating the cost structure is far ahead of current revenue scale. While losses have improved versus some prior years (notably 2023), the company is still far from sustainable earnings power based on the data provided.

Balance Sheet

Leverage appears manageable in TTM (Trailing-Twelve-Months) with low debt relative to equity (debt-to-equity ~0.06) and total debt around $3.3M versus equity around $56.0M. The balance sheet also shows improvement from the higher leverage seen in 2023 (debt-to-equity ~1.11). The key weakness is value creation: returns on shareholders’ equity are sharply negative (TTM return on equity ~-0.84), reflecting persistent losses that can pressure equity over time if not offset by financing or improved results.

Cash Flow

Cash generation is weak: TTM (Trailing-Twelve-Months) operating cash flow is about -$17.3M and free cash flow is about -$17.3M, indicating continued cash burn to fund operations. Free cash flow has improved versus the prior annual period (positive growth rate shown), but the business still relies on external capital unless revenue scales materially or expenses fall. A relative positive is that free cash flow is roughly in line with net losses (free cash flow to net income ~1.0), suggesting losses are not being heavily masked by non-cash items—though the absolute burn remains significant.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	500.00K	400.00K	225.00K	0.00	1.88M	2.37M
Gross Profit	211.00K	400.00K	225.00K	0.00	-1.91M	909.00K
EBITDA	-18.78M	-17.04M	-14.02M	-27.85M	-25.72M	-28.55M
Net Income	-20.11M	-18.38M	-24.91M	-65.01M	-50.39M	-23.21M
Balance Sheet
Total Assets	64.16M	23.18M	28.73M	41.21M	99.41M	146.97M
Cash, Cash Equivalents and Short-Term Investments	49.57M	8.58M	14.21M	7.33M	33.52M	96.97M
Total Debt	3.29M	3.51M	4.46M	17.07M	25.77M	32.72M
Total Liabilities	8.12M	8.30M	7.41M	25.83M	35.92M	38.40M
Stockholders Equity	56.04M	14.88M	21.32M	15.38M	63.48M	108.58M
Cash Flow
Free Cash Flow	-17.30M	-15.32M	-18.76M	-36.17M	-45.13M	-35.23M
Operating Cash Flow	-17.25M	-15.30M	-18.55M	-30.44M	-37.80M	-30.06M
Investing Cash Flow	-21.46M	742.00K	906.00K	7.01M	-5.13M	-26.48M
Financing Cash Flow	55.80M	8.93M	24.49M	2.30M	-5.80M	78.83M

Ibio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IBIO, the sentiment is Positive. The current price of 2.3 is above the 20-day moving average (MA) of 2.28, above the 50-day MA of 1.90, and above the 200-day MA of 1.14, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 54.91 is Neutral, neither overbought nor oversold. The STOCH value of 30.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IBIO.

Ibio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IBIO	55 Neutral	$47.22M	-1.65	-54.50%	―	185.71%	79.03%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NERV	50 Neutral	$175.69M	-2.53	―	―	―	-323.61%
FBLG	44 Neutral	$22.07M	-0.59	-1292.87%	―	―	18.47%
PULM	43 Neutral	$9.39M	-1.52	-79.47%	―	-99.97%	35.59%
CMMB	39 Underperform	$9.54M	-0.90	-73.63%	―	―	53.19%

Ibio Corporate Events

iBio Announces Private Placement to Fund Pipeline Expansion

On January 8, 2026, iBio, Inc. entered into a securities purchase agreement with existing, healthcare-focused institutional investors for an at-the-market private placement of 1,408,481 common shares and pre-funded warrants to purchase up to 9,653,257 additional shares, at a price of $2.35 per share (or $2.349 per pre-funded warrant). The transaction, led by Frazier Life Sciences with Leerink Partners as lead placement agent and LifeSci Capital and Oppenheimer & Co. as co-placement agents, is expected to close on or about January 13, 2026 and generate approximately $26 million in gross proceeds. The funding is earmarked to advance iBio’s preclinical cardiometabolic pipeline, including IBIO-610, IBIO-600 and its myostatin and activin A bispecific programs, as well as other preclinical assets and general corporate purposes, and is expected to extend the company’s cash runway into calendar 2028; the deal also includes customary beneficial-ownership caps on warrant exercises and registration rights obligating iBio to register the resale of the newly issued securities.

The most recent analyst rating on (IBIO) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio Confirms Directors and Auditor at Annual Meeting

On November 20, 2025, iBio, Inc. held its Annual Meeting of Stockholders where four proposals were voted on. The election of two Class II directors, Dr. Martin Brenner and Dr. Alexandra Kropotova, was confirmed for a three-year term. Stockholders ratified Grassi & Co. as the independent auditor for the fiscal year ending June 30, 2026. Additionally, stockholders approved executive compensation on an advisory basis and decided on a one-year frequency for future advisory votes on executive compensation, aligning with the Board’s recommendation.

The most recent analyst rating on (IBIO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.

iBio Regains Nasdaq Compliance with Bid Price Rule

On November 4, 2025, iBio, Inc. announced that it has regained compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. This follows a previous notification on July 29, 2025, indicating non-compliance due to the company’s stock price falling below the required threshold between June 13, 2025, and July 28, 2025. The issue is now resolved, closing the matter.

The most recent analyst rating on (IBIO) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.